Minster Pharmaceuticals plc (AIM: MPM), a drug development company specialising in neurological and psychiatric disorders, reported on 20 April that the company has hired Dr Karl Keegan as its chief financial officer as well as a member of its board.
Keegan, a healthcare analyst, succeeds Robert Aubrey. Aubrey is continuing as an executive director of the company, initially to ensure the smooth transition of the finance function.
Most recently, Keegan was employed with investment bank CanaccordAdams, where he served as managing director and UK head of Equity Research and global head of Life Sciences Research in the six years he was at the company.
Previously, Keegan worked at Banc of America, UBS and DresdnerKleinwort Benson over a period of 11 years. He was also employed in the pharmaceutical industry in research and in commercial strategy, including at SmithKline Beecham Pharmaceuticals.
No comments:
Post a Comment